Association of heart failure in homozygous beta-thalassemia with the major histocompatibility complex

D T Kremastinos1, P Flevari, M Spyropoulou

  • 12nd Department of Cardiology, Athens General Hospital, Athens, Greece. elbee@ath.forthnet.gr

Circulation
|November 16, 1999
PubMed

Insights

Immunogenetic factors may influence heart failure in beta-thalassemia major. Specific HLA alleles were associated with differing risks of developing heart failure in these patients.

Area of Science:

  • Cardiovascular Medicine
  • Immunogenetics
  • Hematology

Background:

  • Heart failure, particularly left ventricular systolic dysfunction, is a major complication and cause of mortality in beta-thalassemia major.
  • Myocarditis, potentially driven by autoimmune mechanisms, is an emerging factor in heart failure pathogenesis in beta-thalassemia major.
  • Investigating immunogenetic factors is crucial to understanding heart failure development in beta-thalassemia major.

Purpose of the Study:

  • To assess the role of major histocompatibility complex (MHC) antigens/alleles (HLA-A, -B, -DR, -DQ) in the development of left-sided heart failure in homozygous beta-thalassemia major patients.
  • To identify potential immunogenetic predispositions to heart failure in this patient population.

Main Methods:

  • A case-control study involving 45 Greek patients with homozygous beta-thalassemia and left-sided chronic heart failure.
  • Comparison with 58 Greek patients with homozygous beta-thalassemia without heart failure and 130 healthy Greek controls.
  • Class I (HLA-A, -B) and Class II (HLA-DR, -DQ) typing performed using complement-mediated lymphocytotoxicity and polymerase chain reaction, respectively.

Main Results:

  • The HLA-DRB1*1401 allele frequency was significantly lower in patients with beta-thalassemia major and heart failure compared to those without heart failure (P(c)=0.02) and healthy controls (P(c)=0.001).
  • Conversely, the HLA-DQA1*0501 allele frequency was significantly higher in patients with heart failure compared to those without heart failure (P(c)=0.04) and healthy controls (P(c)=0.004).

Conclusions:

  • Distinct immunogenetic profiles exist between homozygous beta-thalassemia major patients with and without left-sided heart failure.
  • These findings suggest that genetically determined immune mechanisms may contribute significantly to the pathogenesis of heart failure in beta-thalassemia major.
Abstract

Related Concept Videos

Genetic Lingo01:11

Genetic Lingo

Overview
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...